الديناميكيات الدوائية للسبيرونولاكتون (Arabic Wikipedia)

Analysis of information sources in references of the Wikipedia article "الديناميكيات الدوائية للسبيرونولاكتون" in Arabic language version.

refsWebsite
Global rank Arabic rank
4th place
6th place
2nd place
5th place
1st place
1st place
3rd place
8th place
57th place
1,629th place
6th place
3rd place
120th place
247th place
low place
6,064th place

archive.org

books.google.com

  • Kenneth L. Becker (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. ص. 708, 777, 1087, 1196. ISBN:978-0-7817-1750-2. مؤرشف من الأصل في 2014-06-28. Spironolactone has been used successfully in dosages of 100 to 200 mg daily for the treatment of idiopathic hirsutism and hirsutism associated with polycystic ovarian disease (see Chaps. 96 and 101).184 [...] Spironolactone also is both an antiandrogen and a progestagen, and this explains many of its distressing side effects; decreased libido, mastodynia, and gynecomastia may occur in 50% or more of men, and menometrorrhagia and breast pain may occur in an equally large number of women taking the drug.27
  • Michelle A. Clark؛ Richard A. Harvey؛ Richard Finkel؛ Jose A. Rey؛ Karen Whalen (15 ديسمبر 2011). Pharmacology. Lippincott Williams & Wilkins. ص. 286, 337. ISBN:978-1-4511-1314-3. مؤرشف من الأصل في 2020-04-15.
  • International Agency for Research on Cancer؛ World Health Organization (2001). Some Thyrotropic Agents. World Health Organization. ص. 325–. ISBN:978-92-832-1279-9. مؤرشف من الأصل في 2020-04-15.
  • Pere Ginés؛ Vicente Arroyo؛ Juan Rodés؛ Robert W. Schrier (15 أبريل 2008). Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. John Wiley & Sons. ص. 229, 231. ISBN:978-1-4051-4370-7. مؤرشف من الأصل في 2020-04-15. The most rational treatment of cirrhotic patients with ascites appears to be the administration of an aldosterone antagonist. A stepwise equential therapy with increasing oral doses of an aldosterone antagonist (up to 400 mg/day) may be effective in mobilizing ascites in 60-80% of non-azotemic cirrhotic patients with ascites who do not respond to bed rest and dietary sodium restriction (11,12,74). The effective dosage of aldosterone antagonists depends on plasma aldosterone levels (75). Patients with moderately increased plasma levels require low doses of those drugs (100-150 mg/day), whereas patients with marked hyperaldosteronism may require as much as 200-400 mg/day. A further increase of the dosage up to 500-600 mg/day is of limited usefulness (11,12).
  • Donald W. Seldin؛ Gerhard H. Giebisch (23 سبتمبر 1997). Diuretic Agents: Clinical Physiology and Pharmacology. Academic Press. ص. 630–632. ISBN:978-0-08-053046-8. مؤرشف من الأصل في 2014-07-04. The incidence of spironolactone in men is dose related. It is estimated that 50% of men treated with ≥150 mg/day of spironolactone will develop gynecomastia. The degree of gynecomastia varies considerably from patient to patient but in most instances causes mild symptoms. Associated breast tenderness is common but an inconsistent feature.

doi.org

endocrine.org

issn.org

portal.issn.org

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

researchgate.net

web.archive.org

  • Kenneth L. Becker (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. ص. 708, 777, 1087, 1196. ISBN:978-0-7817-1750-2. مؤرشف من الأصل في 2014-06-28. Spironolactone has been used successfully in dosages of 100 to 200 mg daily for the treatment of idiopathic hirsutism and hirsutism associated with polycystic ovarian disease (see Chaps. 96 and 101).184 [...] Spironolactone also is both an antiandrogen and a progestagen, and this explains many of its distressing side effects; decreased libido, mastodynia, and gynecomastia may occur in 50% or more of men, and menometrorrhagia and breast pain may occur in an equally large number of women taking the drug.27
  • Pelkonen O، Mäenpää J، Taavitsainen P، Rautio A، Raunio H (1998). "Inhibition and induction of human cytochrome P450 (CYP) enzymes". Xenobiotica. ج. 28 ع. 12: 1203–53. DOI:10.1080/004982598238886. PMID:9890159. مؤرشف (PDF) من الأصل في 2015-09-24.
  • Michelle A. Clark؛ Richard A. Harvey؛ Richard Finkel؛ Jose A. Rey؛ Karen Whalen (15 ديسمبر 2011). Pharmacology. Lippincott Williams & Wilkins. ص. 286, 337. ISBN:978-1-4511-1314-3. مؤرشف من الأصل في 2020-04-15.
  • International Agency for Research on Cancer؛ World Health Organization (2001). Some Thyrotropic Agents. World Health Organization. ص. 325–. ISBN:978-92-832-1279-9. مؤرشف من الأصل في 2020-04-15.
  • Pere Ginés؛ Vicente Arroyo؛ Juan Rodés؛ Robert W. Schrier (15 أبريل 2008). Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. John Wiley & Sons. ص. 229, 231. ISBN:978-1-4051-4370-7. مؤرشف من الأصل في 2020-04-15. The most rational treatment of cirrhotic patients with ascites appears to be the administration of an aldosterone antagonist. A stepwise equential therapy with increasing oral doses of an aldosterone antagonist (up to 400 mg/day) may be effective in mobilizing ascites in 60-80% of non-azotemic cirrhotic patients with ascites who do not respond to bed rest and dietary sodium restriction (11,12,74). The effective dosage of aldosterone antagonists depends on plasma aldosterone levels (75). Patients with moderately increased plasma levels require low doses of those drugs (100-150 mg/day), whereas patients with marked hyperaldosteronism may require as much as 200-400 mg/day. A further increase of the dosage up to 500-600 mg/day is of limited usefulness (11,12).
  • Corvol P، Michaud A، Menard J، Freifeld M، Mahoudeau J (يوليو 1975). "Antiandrogenic effect of spirolactones: mechanism of action". Endocrinology. ج. 97 ع. 1: 52–8. DOI:10.1210/endo-97-1-52. PMID:166833. مؤرشف من الأصل في 2020-04-15.
  • Donald W. Seldin؛ Gerhard H. Giebisch (23 سبتمبر 1997). Diuretic Agents: Clinical Physiology and Pharmacology. Academic Press. ص. 630–632. ISBN:978-0-08-053046-8. مؤرشف من الأصل في 2014-07-04. The incidence of spironolactone in men is dose related. It is estimated that 50% of men treated with ≥150 mg/day of spironolactone will develop gynecomastia. The degree of gynecomastia varies considerably from patient to patient but in most instances causes mild symptoms. Associated breast tenderness is common but an inconsistent feature.